Analyses by treatment timing, cumulative dose, and stunting supported the overall finding, though early-initiation and female subgroup data were limited.
Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.